FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3097803109> ?p ?o ?g. }

• W3097803109 endingPage "1" @default.
• W3097803109 startingPage "1" @default.
• W3097803109 abstract "Platelets play a key role in innate immunity and can interact with bacteria through multiple molecular mechanisms. One key receptor for platelet-bacteria interactions is FcγRIIa, a low affinity IgG immune receptor found on the surface of platelets, which is associated with platelet aggregation, phagocytosis and the release of bactericidal substances and cytokines from alpha and dense granules. The signalling pathways that regulate FcγRIIa mediated platelet responses to bacteria are not fully understood. Downstream of the FcγRIIa receptor is the protein Bruton's tyrosine kinase (Btk) and potentially other Tec family kinases, yet the role of these kinases in platelet-bacteria interactions is unknown. Btk is a therapeutic target in chronic lymphocytic leukaemia (CLL) with inhibitors of Btk (iBtks) including ibrutinib and acalabrutinib. However, iBtks have off-target effects on platelets, inhibiting aggregation with associated haemorrhagic side effects. iBtk treatment is also associated with a higher incidence of infection in CLL patients. The effect of iBtks on platelet immune function has not been evaluated. We hypothesise that Btk has a role in platelet FcγRIIa signalling in response to bacterial agonists, and that iBtks inhibit such responses, contributing towards the increased risk of infection seen with such therapies in CLL. We show that ibrutinib and acalabrutinib inhibit healthy donor FcγRIIa-mediated platelet aggregation, alpha and dense granule release in response to incubation with Staphylococcus aureus and Escherichia coli, and also in response to FcγRIIa crosslinking with the monoclonal antibody IV.3 (anti-FcγRIIa). The observed lack of granule secretion will reduce the bactericidal substances released by the platelet, as well as the amount of cytokine and chemokine secretion limiting cross-talk with other immune cells. Phosphorylation of Btk at tyrosine 223 (a marker of Btk activation) was detected in response to FcγRIIa agonists, and was inhibited by both ibrutinib and acalabrutinib. Little is known about the effect of iBtk treatment on CLL-platelet responses to bacteria. CLL patients tend to be on concurrent medications for comorbid conditions that could alter platelet responses. We show that treatment-naïve and ibrutinib-treated CLL platelets have aggregation and alpha granule release to thrombin receptor activator peptide 6 and ADP comparable to healthy controls, indicating that CLL platelet responses to these FcγRIIa-independent agonists are normal. Moreover, platelets derived from iBtk naïve CLL patients aggregate normally to bacteria in the presence of autologous plasma. However, platelets from ibrutinib-treated CLL patients have significantly inhibited aggregation and alpha granule release in response to S.aureus, E.coli, and IV.3 crosslinking. Moreover, Btk is phosphorylated at Y223 in response to bacterial agonists in treatment-naïve, but not in ibrutinib-treated CLL platelets, highlighting the lack of Btk activation in iBtk-treated patients. An X-linked agammaglobulinaemia (XLA) patient with a known Btk loss of function mutation was examined to investigate if Btk is vital for the FcγRIIa pathway. XLA-derived platelets aggregated normally in response to multiple bacterial species, suggesting Btk is redundant in mediating platelet aggregatory responses to bacteria. These results suggest that other Tec family kinases might have a role in platelet FcγRIIa activation to bacteria, which could be affected by iBtk treatment too. In conclusion, we propose that iBtks impair the FcγRIIa pathway in platelets, reducing platelet-bacteria responses, possibly contributing to the increased risk of infections in observed in CLL. Disclosures No relevant conflicts of interest to declare." @default.
• W3097803109 created "2020-11-09" @default.
• W3097803109 creator A5011803984 @default.
• W3097803109 creator A5026887261 @default.
• W3097803109 creator A5035714719 @default.
• W3097803109 creator A5045634788 @default.
• W3097803109 creator A5078478289 @default.
• W3097803109 creator A5087456324 @default.
• W3097803109 creator A5088985148 @default.
• W3097803109 date "2020-11-05" @default.
• W3097803109 modified "2023-09-30" @default.
• W3097803109 title "Bruton's Tyrosine Kinase Inhibitors Impair Fcγriia-Mediated Responses of Healthy Donor Platelets and Chronic Lymphocytic Leukaemia Derived Platelets to Bacteria" @default.
• W3097803109 doi "https://doi.org/10.1182/blood-2020-142624" @default.
• W3097803109 hasPublicationYear "2020" @default.
• W3097803109 type Work @default.
• W3097803109 sameAs 3097803109 @default.
• W3097803109 citedByCount "0" @default.
• W3097803109 crossrefType "journal-article" @default.
• W3097803109 hasAuthorship W3097803109A5011803984 @default.
• W3097803109 hasAuthorship W3097803109A5026887261 @default.
• W3097803109 hasAuthorship W3097803109A5035714719 @default.
• W3097803109 hasAuthorship W3097803109A5045634788 @default.
• W3097803109 hasAuthorship W3097803109A5078478289 @default.
• W3097803109 hasAuthorship W3097803109A5087456324 @default.
• W3097803109 hasAuthorship W3097803109A5088985148 @default.
• W3097803109 hasConcept C203014093 @default.
• W3097803109 hasConcept C2777938653 @default.
• W3097803109 hasConcept C2778461978 @default.
• W3097803109 hasConcept C2779878957 @default.
• W3097803109 hasConcept C2779931124 @default.
• W3097803109 hasConcept C3018697912 @default.
• W3097803109 hasConcept C35174551 @default.
• W3097803109 hasConcept C42362537 @default.
• W3097803109 hasConcept C62478195 @default.
• W3097803109 hasConcept C86803240 @default.
• W3097803109 hasConcept C8891405 @default.
• W3097803109 hasConcept C89560881 @default.
• W3097803109 hasConcept C90059517 @default.
• W3097803109 hasConcept C95444343 @default.
• W3097803109 hasConceptScore W3097803109C203014093 @default.
• W3097803109 hasConceptScore W3097803109C2777938653 @default.
• W3097803109 hasConceptScore W3097803109C2778461978 @default.
• W3097803109 hasConceptScore W3097803109C2779878957 @default.
• W3097803109 hasConceptScore W3097803109C2779931124 @default.
• W3097803109 hasConceptScore W3097803109C3018697912 @default.
• W3097803109 hasConceptScore W3097803109C35174551 @default.
• W3097803109 hasConceptScore W3097803109C42362537 @default.
• W3097803109 hasConceptScore W3097803109C62478195 @default.
• W3097803109 hasConceptScore W3097803109C86803240 @default.
• W3097803109 hasConceptScore W3097803109C8891405 @default.
• W3097803109 hasConceptScore W3097803109C89560881 @default.
• W3097803109 hasConceptScore W3097803109C90059517 @default.
• W3097803109 hasConceptScore W3097803109C95444343 @default.
• W3097803109 hasIssue "Supplement 1" @default.
• W3097803109 hasLocation W30978031091 @default.
• W3097803109 hasOpenAccess W3097803109 @default.
• W3097803109 hasPrimaryLocation W30978031091 @default.
• W3097803109 hasRelatedWork W2098657513 @default.
• W3097803109 hasRelatedWork W2100751415 @default.
• W3097803109 hasRelatedWork W2601929339 @default.
• W3097803109 hasRelatedWork W2983342945 @default.
• W3097803109 hasRelatedWork W3000362980 @default.
• W3097803109 hasRelatedWork W3016355356 @default.
• W3097803109 hasRelatedWork W3097803109 @default.
• W3097803109 hasRelatedWork W4327933233 @default.
• W3097803109 hasRelatedWork W4366989200 @default.
• W3097803109 hasRelatedWork W95648326 @default.
• W3097803109 hasVolume "136" @default.
• W3097803109 isParatext "false" @default.
• W3097803109 isRetracted "false" @default.
• W3097803109 magId "3097803109" @default.
• W3097803109 workType "article" @default.